Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO-3 randomized trial.
Daniel FeldmanDavide CaoSamantha SartoriZhongjie ZhangChristian HengstenbergChristophe TronProdromos AnthopoulosJulian D WidderNicolas MeneveauPieter R StellaMarkus FerrariRaban JegerRoberto VioliniNicolas DumonteilShiwei ChenRuiqi YanJohny NicolasVictor RazukAlessandro SpiritoBirgit VogelRoxana MehranGeorge D DangasPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2023)
CAD was not associated with a higher short-term risk of NACE or major bleeding after TAVR. Periprocedural anticoagulation with bivalirudin did not show any advantage over UFH in patients with and without CAD.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- aortic stenosis
- transcatheter aortic valve replacement
- atrial fibrillation
- aortic valve
- coronary artery bypass grafting
- cardiovascular events
- venous thromboembolism
- direct oral anticoagulants
- ejection fraction
- catheter ablation
- heart failure
- left ventricular
- type diabetes
- acute coronary syndrome
- cardiovascular disease